FDA's 'Drug Safety Priorities' Working Group Politicized Under Biden Administration

Retrieved on: 2025-02-19 16:31:40

Tags for this article:

Food and Drug Administration

Puberty

Puberty blocker

Center for Drug Evaluation and Research

Off-label use

Pharmacovigilance

Click the tags to see associated articles and topics

FDA's 'Drug Safety Priorities' Working Group Politicized Under Biden Administration. View article details on hiswai:

Summary

The article discusses FDA's ideological decision-making affecting drug safety communication, contrasting its handling of puberty blockers and COVID-19 treatments with its response to the COVID vaccine, emphasizing a need for nonpartisan pharmacovigilance. Tags align with discussing deficiencies in FDA views on puberty blockers and their off-label use.

Article found on: www.dailysignal.com

View Original Article